Cell Therapy

Gene Therapy Enables Child With AADC Deficiency to Walk and Run
Research & Development Gene Therapy Enables Child With AADC Deficiency to Walk and Run

The medical landscape for rare genetic disorders is undergoing a profound transformation as advanced biotechnologies move from experimental stages to life-changing clinical realities for pediatric patients. For a five-year-old boy born with aromatic L-amino acid decarboxylase (AADC) deficiency, a

Can Dual-Target CAR T-Cell Therapy Cure Pediatric Leukemia?
Research & Development Can Dual-Target CAR T-Cell Therapy Cure Pediatric Leukemia?

The diagnosis of B-cell acute lymphoblastic leukemia often strikes families like a sudden, life-altering storm, transforming a normal childhood into a grueling cycle of hospital stays, invasive procedures, and toxic chemical regimens. For decades, the medical community relied almost exclusively on

Can MHC Class I Shield Cancer From CD4+ Helper T Cells?
Research & Development Can MHC Class I Shield Cancer From CD4+ Helper T Cells?

For decades, the fundamental understanding of the human immune system relied on a strict division of labor where specific molecules directed the activities of specialized cellular defenders against pathogens and tumors. This biological framework, often referred to as the MHC dichotomy, suggested

How Can Nanoparticles Scale Up Therapeutic Exosome Production?
Research & Development How Can Nanoparticles Scale Up Therapeutic Exosome Production?

The transition from traditional stem cell therapies to more refined exosome-based treatments represents one of the most significant shifts in regenerative medicine during the middle of this decade. While stem cells offer immense healing potential, they carry inherent risks such as unwanted

Can Korean Biotech Redefine Next-Gen Cancer Treatments?
Research & Development Can Korean Biotech Redefine Next-Gen Cancer Treatments?

The 2026 American Association for Cancer Research annual meeting in San Diego stands as a definitive proving ground where South Korean biotechnology firms must transition from theoretical promise to clinical validation. Unlike later-stage conferences such as ASCO or ESMO, the AACR provides a unique

Can Engineered CAR-T Cells Breach Solid Tumor Defenses?
Research & Development Can Engineered CAR-T Cells Breach Solid Tumor Defenses?

While Chimeric Antigen Receptor (CAR) T-cell therapy has successfully transformed the clinical outlook for patients with liquid cancers, its efficacy against solid tumors remains one of the most significant hurdles in modern oncology. Unlike the accessible environment of the bloodstream, where

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later